![Matthew Del Giudice](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 16 000 $ al 30/06/2026
Matthew Paul Del Giudice is currently an Independent Director at MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc., both positions starting in 2024.
Formerly, the role was Head-General Overnight Emergency Radiologist at The Cleveland Clinic Foundation from 2021 to 2022.
Education includes undergraduate studies at the University of Illinois At Urbana–Champaign and a doctorate from Stritch School of Medicine.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 21/05/2026 | 12.500 ( 0,04 % ) | 16 000 $ | 30/06/2026 | |
| 12/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MIRA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 13/03/2024 |
| TELOMIR PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 12/08/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
The Cleveland Clinic Foundation
 The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Corporate Officer/Principal | 01/05/2022 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
Stritch School of Medicine
 Stritch School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIRA Pharmaceuticals, Inc.
 MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
Telomir Pharmaceuticals, Inc.
 Telomir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops a novel small molecule as the first regulator of telomere length and genomic stability | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
